Staff Reports | Community Updates
Banner MD Anderson Cancer Center is offering a new hope for patients with advanced melanoma who no longer respond to standard immunotherapies.
In a Phase II clinical trial, researchers found that a novel investigational treatment — RP1, a genetically engineered virus — used in combination with the immunotherapy drug nivolumab significantly shrank tumors in about one in three patients whose disease had progressed after standard treatment…